ALUMIS INC. Logo

ALUMIS INC.

Develops targeted oral therapies for immune-mediated diseases using precision immunology.

ALMS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
280 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. The company utilizes a precision immunology approach, powered by a proprietary data analytics platform, to drive smarter therapeutic development. Alumis is advancing a late-stage portfolio of next-generation targeted oral therapies designed to replace broad immunosuppression with treatments that address the key drivers of immune dysfunction. Its mission is to optimize patient outcomes and significantly improve the lives of individuals with autoimmune conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALUMIS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALUMIS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALUMIS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX
Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX
Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT

Talk to a Data Expert

Have a question? We'll get back to you promptly.